Abstract
Bristol-Myers Squibb has named a new chief scientific officer. The appointment is the third replacement of a big pharma company research head since the beginning of the year—and probably the most amicable one. Francis Cuss will become BMS’s chief scientific officer on July 1, after the departure of Elliott Sigal, 61, who has been with the firm since 1997. Cuss, 58, joined the company in 2003 and has served in several scientific leadership roles. The change of guard at BMS follows the departure of R&D heads at AstraZeneca and Merck & Co. in January and April, respectively. Although CEOs rarely speak ill in public about departing executives, it was clear that AstraZeneca CEO Pascal Soriot was dissatisfied with Martin Mackay, his R&D chief. Mackay left the job immediately and was not replaced. Merck CEO Kenneth C. Frazier was also reportedly not happy with his R&D head, Peter S. Kim. Still, ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.